Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Sino Biopharmaceutical (SBMFF) Income from Continuous Operations data is not available for the most recently reported fiscal quarter, ending 2024-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Income from Continuous Operations |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$3.48B |
|
$1.11B |
|
$5.73B |
|
$9.21B |
|
$3.03B |
|
$139.48M |
|
$363.60M |
|
$3.39B |
|
$5.82B |
|
$5.39B |
|
$5.82B |
|
18.79B |
|
| Cash Flow Statement Financials | |
$425.14M |
|
$-281.85M |
|
$-566.14M |
|
$1.04B |
|
$617.23M |
|
$-419.22M |
|
-- |
|
$-122.80M |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|